Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

C Leduc,J P Merlio,B Besse, H Blons, D Debieuvre, P P Bringuier,I Monnet,I Rouquette, S Fraboulet-Moreau, A Lemoine, D Pouessel, J Mosser,F Vaylet, A Langlais, P Missy, F Morin, D Moro-Sibilot, J Cadranel, F Barlesi,M Beau-Faller

Annals of oncology : official journal of the European Society for Medical Oncology（2017）

引用 69|浏览31

暂无评分

摘要

EGFR mutation type can inform the most appropriate treatment. Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.

查看译文

关键词

epidemiology,epidermal growth factor receptor gene (EGFR) mutations,non-small-cell lung cancer (NSCLC),tyrosine-kinase inhibitors (TKI)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要